Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,833
  • Shares Outstanding, K 60,583
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,470 K
  • 60-Month Beta 0.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.31
Trade CLBS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.41
  • Most Recent Earnings $-0.11 on 08/04/22
  • Latest Earnings Date 11/03/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.12
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3820 +11.62%
on 09/14/22
0.6500 -34.40%
on 09/14/22
-0.1108 (-20.63%)
since 08/12/22
3-Month
0.3820 +11.62%
on 09/14/22
0.6500 -34.40%
on 09/14/22
-0.0736 (-14.72%)
since 06/14/22
52-Week
0.3820 +11.62%
on 09/14/22
1.2400 -65.61%
on 10/15/21
-0.7936 (-65.05%)
since 09/14/21

Most Recent Stories

More News
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations ...

CLBS : 6.3960 (-16.44%)
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata...

CLBS : 6.3960 (-16.44%)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PING : 28.50 (+0.11%)
CLBS : 6.3960 (-16.44%)
MANT : 95.98 (-0.01%)
CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosciences, Inc. (NasdaqCM: CLBS)...

CLBS : 6.3960 (-16.44%)
Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Top-line data from all subjects expected by the first quarter of 2023...

CLBS : 6.3960 (-16.44%)
Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...

CLBS : 6.3960 (-16.44%)
Caladrius Biosciences to Present at the BIO International Convention 2022

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...

CLBS : 6.3960 (-16.44%)
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps...

CLBS : 6.3960 (-16.44%)
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage...

CLBS : 6.3960 (-16.44%)
CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosciences, Inc. (NasdaqCM: CLBS)...

CLBS : 6.3960 (-16.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve...

See More

Key Turning Points

3rd Resistance Point 0.8583
2nd Resistance Point 0.7541
1st Resistance Point 0.5903
Last Price 6.3960
1st Support Level 0.3223
2nd Support Level 0.2181
3rd Support Level 0.0543

See More

Last Price 6.3960
52-Week High 1.2400
Fibonacci 61.8% 0.9122
Fibonacci 50% 0.8110
Fibonacci 38.2% 0.7098
52-Week Low 0.3820

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar